JAK3 and psoriasis: JAK1 inhibitors, for example, small molecule tofacitinib that inhibits JAK1 and JAK3, are used for treatment of rheumatoid arthritis and are currently tested in other immunological disorders, such as psoriasis and inflammatory bowel disease.